RxDoctor Payments Data

Denise Gomez, MD

Internal Medicine · Oceanside, CANPI 1407871817

Payments from drug & device makers

$5,893in general payments, 2019–2025

Across 257 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$2K
  • AbbVie$572
  • Janssen Products, LP$416
  • Johnson & Johnson$294
  • Insulet Corporation$173
  • plus $668 from 13 others

What the payments were for

  • Food & beverage$5,74898%
  • Education$1452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,893 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,742
Medicare patients
68
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin183$190,527
GenvoyaElviteg/Cob/Emtri/Tenof Alafen30$110,383
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$100,850
OzempicSemaglutide75$77,528
BiktarvyBictegrav/Emtricit/Tenofov Ala18$66,638
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$52,979
TradjentaLinagliptin56$51,135
JanuviaSitagliptin Phosphate44$44,485
TrulicityDulaglutide39$39,536
RexultiBrexpiprazole28$38,135
InvokanaCanagliflozin45$36,728
EliquisApixaban29$30,585
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$27,317
RybelsusSemaglutide24$24,254
EntrestoSacubitril/Valsartan14$19,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$2,078$177,02248 claims
Novo NordiskOzempic, Rybelsus$39$101,78299 claims
Janssen Products, LPSymtuza$416$52,97912 claims
Johnson & JohnsonInvokana$294$36,72845 claims
GSKTrelegy Ellipta$13$27,31733 claims
AstraZenecaFarxiga$104$17,88422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →